Internal Medicine, Rheumatology · San Pedro, CA
NPI
1811183585
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1360 W 6th St Ste 310
San Pedro, CA, 90732
Phone (562) 529-7772
Groups this clinician bills Medicare through
Medicare paid, 2024
$68K
1,037 services
Medicare patients, 2024
265
Average age 67
Drug cost, 2024
$9.1M
4,845 prescriptions
Company payments, 2025
$2,540
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeremy Anuntiyo was code 99213 (office e&m - established), 433 times for 220 patients. In total Jeremy Anuntiyo billed 1,037 services in 11 codes, and Medicare paid $68K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 433 | 220 | $72.32 | $31K |
| 99214 Office E&M - Established | Office | 252 | 141 | $104.30 | $26K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 133 | 21 | $0.78 | $103 |
| 99204 Office E&M - New | Office | 40 | 40 | $136.15 | $5,446 |
| 20610 Joint Injection | Office | 22 | 17 | $54.60 | $1,201 |
| 96372 Injection Administration | Office | 22 | 15 | $11.41 | $251 |
By year: 2022 $67K for 859 services; 2023 $73K for 1,080 services; 2024 $68K for 1,037 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jeremy Anuntiyo prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 766 prescriptions and refills. In total Jeremy Anuntiyo wrote 4,845 Medicare prescriptions that cost $9.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 766 | 1,579 | 203 | $30K |
| Prednisone Generic | 585 | 921 | 143 | $4,007 |
| Methotrexate Methotrexate Sodium | 431 | 862 | 110 | $10K |
| Enbrel Sureclick Etanercept | 362 | 362 | 42 | $2.7M |
| Benlysta Belimumab | 251 | 253 | 37 | $1.2M |
| Tramadol Hcl Generic | 218 | 218 | 45 | $977 |
| Rinvoq Upadacitinib | 189 | 195 | 29 | $1.2M |
| Gabapentin Generic | 152 | 243 | 38 | $1,767 |
| Kevzara Sarilumab | 115 | 123 | 15 | $531K |
| Humira(Cf) Pen Adalimumab | 91 | 97 | 12 | $649K |
| Orencia Clickject Abatacept | 87 | 88 | Under 11 | $485K |
| Alendronate Sodium Generic | 83 | 206 | 26 | $439 |
| Actemra Actpen Tocilizumab | 81 | 81 | 12 | $213K |
| Leflunomide Generic | 80 | 195 | 29 | $6,804 |
| Cyclobenzaprine Hcl Generic | 76 | 98 | 14 | $379 |
Brand drugs: - claims; generic drugs: 3,324 claims; opioid claims: 218.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeremy Anuntiyo $2,540 ($2,540 in general payments such as food, travel and fees) from 17 companies. The largest payer was Abbvie Inc. with $785.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 61 | $785 |
| Janssen Biotech, Inc. JNJ | 10 | $307 |
| Pfizer Inc. PFE | 14 | $245 |
| UCB, Inc. UCB.BR | 7 | $245 |
| Amgen Inc. AMGN | 15 | $233 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $143 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $106 |
| GlaxoSmithKline, LLC. GSK | 5 | $93.28 |
| Lilly USA, LLC LLY | 3 | $80.35 |
| Genzyme Corporation SNY | 3 | $66.88 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.